secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2022-04-14T23:59:59+00:00
Accession:  0000950170-22-005694
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma CMO Christopher Slapak to retire effective May 6, 2022
--------------------------------------------------------------------

- Dr. Christopher Slapak, Chief Medical Officer, will terminate employment on May 6, 2022 due to retirement.
- Severance benefits consistent with the Company's Executive Severance and Change in Control Benefits Plan.
- Separation agreement to be filed as an exhibit to Q2 2022 Form 10-Q.
- No successor appointed as of the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000095017022005694/0000950170-22-005694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000095017022005694/vor-20220411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer